| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.041 | 0.5 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.01 | 0.8 |